• Axsome Plans to Try Again After Failure in Treatment-Resistant Depression

    1 month ago - By Xconomy

    An experimental Axsome Therapeutics drug for treatment-resistant depression has fallen short of the main goal of a late-stage test. But the company says the pill is showing enough promise to warrant trying another Phase 3 study. Axsome tested its drug, AXS-05, in patients with major depressive disorder who had previously failed to respond to treatment with antidepressants. The study, which enrolled 312 patients, compared the Axsome drug to the antidepressant bupropion. Patients were evaluated according to the Montgomery-Åsberg depression rating scale, a diagnostic questionnaire used to...
    Read more ...